Angiocrine Bioscience is developing curative cell therapies to use for regenerative medicine. Endothelial cells that line blood vessels are important for organ function, but also play an active role in repairing tissue damage by expressing reparative angiocrine factors. Unfortunately, endothelial cell dysfunction occurs with age reducing the repair capacity. Angiocrine is creating engineered cord endothelial cells (E-CEL) to create various Advanced Reparative Medicines using their proprietary platform technology. Preclinical studies support regeneration of various organs following E-CEL treatment in animal models of chemo-radiation toxicities. Currently Angiocrine has two E-CEL Therapy products in clinical testing and five ‘next-generation’ E-CEL Therapies in research stage development.
Claim company profile to post jobs directly on this page and this website.